Warfarin suppliers
Warfarin
- CAS:
- 81-81-2
- MF:
- C19H16O4
- MW:
- 308.33
Suppliers by country/region
Company Type
Properties
- Melting point:
- 162-164 °C(lit.)
- Boiling point:
- 356°C
- Density
- 1.1411 (rough estimate)
- vapor pressure
- 0.09 at 22 °C (NIOSH, 1997)
- refractive index
- 1.4434 (estimate)
- Flash point:
- 2℃
- storage temp.
- 2-8°C
- solubility
- Soluble in benzene, 1,4-dioxane (Weast, 1986), and acetone (Sax and Lewis, 1987). Moderately soluble in methanol, ethanol, isopropanol, and some oils (Windholz et al., 1983). Also soluble in toluene.
- form
- Crystalline
- pka
- pKa 4.90±0.01(H2O t = 25±0.5 I = 0.15 (KCl))(Approximate)
- color
- Colorless
- Odor
- odorless
- Water Solubility
- Practically insoluble
- Merck
- 13,10097
- BRN
- 8868198
- Exposure limits
- NIOSH REL: TWA 0.1 mg/m3, IDLH 100 mg/m3; OSHA PEL: 0.1 mg/m3; ACGIH TLV: TWA 0.1 mg/m3.
- LogP
- 2.600
Safety Information
- Symbol(GHS)
GHS06,GHS08,GHS09
- Signal word
- Danger
- Hazard statements
- H300+H310+H330-H360D-H372-H411
- Precautionary statements
- P202-P264-P273-P280-P302+P352+P310-P304+P340+P310
- Hazard Codes
- T,T+,Xn,F
- Risk Statements
- 61-48/25-52/53-28-21-36-20/21/22-11
- Safety Statements
- 53-45-61-52-36/37-28-26-16
- RIDADR
- UN 2811 6.1/PG 1
- OEB
- D
- OEL
- TWA: 0.1 mg/m3
- WGK Germany
- 3
- RTECS
- GN4550000
- HazardClass
- 6.1(a)
- PackingGroup
- I
- HS Code
- 29322090
- Toxicity
- EC50 (24-hour) for Daphnia magna 88.8 mg/L (Lilius et al., 1995); acute oral LD50 for rats 186 mg/kg (Hartley and Kidd, 1987), 3 mg/kg (RTECS, 1985)
- IDLA
- 100 mg/m3
Use
Warfarin is tasteless and colorless. It is a widely used as anticoagulant (which stops the blood clotting) in the treatment and prevention of thrombosis, in the treatment for chronic atrial fibrillation, mechanical valves, pulmonary embolism, and dilated cardiomyopathy. Warfarin is metabolized primarily via oxidation in the liver by CYP2C9, and exerts its anticoagulant effect by inhibiting the protein vitamin K epoxide reductase complex, subunit 1 (VKORC1). Warfarin therapy can be associated with significant bleeding complications. Achieving a safe therapeutic response can be difficult because of warfarins narrow therapeutic index and great individual variability in the dose required, which is mostly a consequence of individual genetic variants: it is influenced by ageing, co-prescribed drugs, diet, alcohol consumption, and comorbid conditions. To maintain a therapeutic level of anti-thrombosis and to minimize the risk of bleeding complications, warfarin therapy requires intensive monitoring via the INR to guide its dosing. It is also used as the first generation of anticoagulant rodenticides.
156 supplier list of "Warfarin"